Titanium implant osseointegration in rheumatoid arthritis patients: Two case reports
Journal of Dental School, Shahid Beheshti University of Medical Sciences,
Vol. 35 No. 4 (2017),
5 March 2019
Case Implant rehabilitation in patients suffering from rheumatoid arthritis (RA) has been reported an improvement in the quality of life. Implanttreatment success depends on many factors like achievement of appropriate osseointegration. There are many controversies about theinteractions between anti-rheumatic drugs and osseointegration. Moreover, the scientific evidence regarding implant survival in RApatients are scarce. This study presents two case reports including 65- and 51-year-old women who have used low-dose methotrexate andother anti-rheumatic drugs treated by dental implants. After 4-years follow-up, the patients are satisfied of function and aesthetics. Stablebone level was seen around all implants radiographically. Because of the lack of agreement in implant treatment protocol in RA patient,more studies are suggested.
- implant osseointegration
- low-dose methotrexate
- rheumatoid arthritis
How to Cite
Mavrogenis AF, Dimitriou R, Parvizi J, Babis GC. Biology of implant osseointegration. J Musculoskelet Neuronal Interact. 2009;9(2):61–71.
Jaworski ZF. Physiology and pathology of bone remodeling. Cellular basis of bone structure in health and in osteoporosis. Orthop Clin North Am. 1981;12:485–512.
Carvas JB, Pereira RM, Bonfa E, Silveira CA, Lima LL, Caparbo Vde F, et al. No deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model. Clinics. 2011;66:1055–1059.
Annussek T, Kleinheinz J, Thomas S, Joos U, Wermker K. Short time administration of antirheumatic drugs—Methotrexate as a strong inhibitor of osteoblast’s proliferation in vitro. Head Face Med. 2012;8:26.
May KP, West SG, McDermott MT, Huffer WE. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum. 1994;37:201–206.
Boulos P, Ioannidis G, Adachi JD. Glucocorticoid-induced osteoporosis. Curr Rheum Rep. 2000;2:53–61.
Carvas JS, Pereira RM, Caparbo VF, Fuller P, Silveira CA, Lima LA, et al. A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration. Osteoporos Int. 2010;21:1723–1729.
Hoult JR, Moore PK. Sulphasalazine is a potent inhibitor of prostaglandin 15-hydroxydehydrogenase: possible basis for therapeutic action in ulcerative colitis. Brit J Pharmacol. 1978;64:6–8.
Ouanounou A, Hassanpour S, Glogauer M. The influence of systemic medications on osseointegration of dental implants. J Can Dent Assoc. 2016;82:g7.
Patel S, Patel G, Johnson D, Ogunremi L, Barron J. Effect of low dose weekly methotrexate on bone mineral density and bone turnover. Ann Rheum Dis. 2003;62:186–187.
Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol. 1996;132:184–187.
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–1108.
Magyari L, Varszegi D, Kovesdi E, Sarlos P, Farago B, Javorhazy A, et al. Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. World J Orthoped. 2014;5:516– 536.
Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72:1897–1904.
Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol. 2009;21:216–223.
Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007;46:1520–1524.
Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Brit J Pharmacol. 2003;138:501–511.
Meister B, Gassner I, Streif W, Dengg K, Fink FM. Methotrexate osteopathy in infants with tumors of the central nervous system. Med Pediatr Oncol. 1994;23:493–496.
van der Bijl AE, Zijlstra TR, Engelage AH, Posthuma BJ, van Veen GJ. [Three patients with a fracture during methotrexate use, possibly due to methotrexate osteopathy]. Ned Tijdschr Geneeskd. 2008;152:2357–2360.
Preston SJ, Diamond T, Scott A, Laurent MR. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis. 1993;52:582–585.
Krennmair G, Seemann R, Piehslinger E. Dental implants in patients with rheumatoid arthritis: clinical outcome and peri-implant findings. J Clin Periodontol. 2010;37:928–936.
Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2–13.
Fu JH, Bashutski JD, Al-Hezaimi K, Wang HL. Statins, glucocorticoids, and nonsteroidal anti-inflammatory drugs: Their influence on implant healing. Implant Dent. 2012;21:362–367.
Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am. 1998;27:465–483.
Smith RA, Berger R, Dodson TB. Risk factors associated with dental implants in healthy and medically compromised patients. Int J Oral Maxillofac Implants. 1992;7:367–372.
Cranin AN. Endosteal implants in a patient with corticosteroid dependence. J Oral implantol. 1991;17:414–417.
Fujimoto T, Niimi A, Sawai T, Ueda M. Effects of steroid-induced osteoporosis on osseointegration of titanium implants. Int J Oral Maxillofac implants. 1998;13:183–189.
Beumer J, Landesman H, Terry B, Davis W, Davis C. Prosthodontic and surgical aspects of treatment planning for reconstructive surgery. In Reconstructive Preprothetic Oral and Maxillofacial Surgery; Saunders: Philadelphia, 1986; pp. 41–60.
Bencharit S, Reside GJ, Howard-Williams EL. Complex prosthodontic treatment with dental implants for a patient with polymyalgia rheumatica: a clinical report. Int J Oral Maxillofac Implants. 2010;25(6):1241–1245.
Werner SB, Tessler J, Guglielmotti MB, Cabrini RL. Effect of dexamethasone on osseointegration: A preliminary experimental study. J Oral Implantol. 1996;22:216–219.
Simon AM, Manigrasso MB, O’Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res. 2002;17:963–976.
Beck A, Krischak G, Sorg T, Augat P, Farker K, Merkel U, et al. Influence of diclofenac (group of nonsteroidal anti-inflammatory drugs) on fracture healing. Arch Orthop Trauma Surg. 2003;123:327–332.
Ribeiro FV, Nociti FH, Jr., Sallum EA, Casati MZ. Effect of aluminum oxide- blasted implant surface on the bone healing around implants in rats submitted to continuous administration of selective cyclooxygenase-2 inhibitors. Int J Oral Maxillofac Implants. 2009;24:226–233.
Pablos AB, Ramalho SA, Konig B, Jr., Furuse C, de Araujo VC, Cury PR. Effect of meloxicam and diclofenac sodium on peri-implant bone healing in rats. J Periodontol. 2008;79:300–306.
Alissa R, Sakka S, Oliver R, Horner K, Esposito M, Worthington HV,
et al. Influence of ibuprofen on bone healing around dental implants: a randomised double-blind placebo-controlled clinical study. Eur J Oral Implantol. 2009;2:185–199.
Ella B, Lasserre JF, Blanchard JP, Fricain JC. A 4-year follow-up of two complete mandibular implant-supported removable prostheses in a patient with severe rheumatoid polyarthritis: case report. Int J Oral Maxillofac Implants. 2011;26:e19–e22.
Eder A, Watzek G. Treatment of a patient with severe osteoporosis and chronic polyarthritis with fixed implant-
supported prosthesis: a case report. Int J Oral Maxillofac Implants. 1999;14:587–590.
- Abstract Viewed: 255 times
- PDF Downloaded: 77 times